Vandetanib in Advanced Medullary Thyroid Cancer: Review of Adverse Event Management Strategies
Published 2013 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Vandetanib in Advanced Medullary Thyroid Cancer: Review of Adverse Event Management Strategies
Authors
Keywords
Adverse effects, Antineoplastic agents/adverse effects, Cardiovascular, Dermatology, Medullary thyroid cancer, Medullary thyroid carcinoma, Patient safety, Piperidines/therapeutic use, Protein kinase inhibitors, Thyroid neoplasms/drug therapy, Vandetanib
Journal
ADVANCES IN THERAPY
Volume 30, Issue 11, Pages 945-966
Publisher
Springer Nature
Online
2013-11-19
DOI
10.1007/s12325-013-0069-5
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Body Composition Variation and Impact of Low Skeletal Muscle Mass in Patients With Advanced Medullary Thyroid Carcinoma Treated With Vandetanib: Results From a Placebo-Controlled Study
- (2013) Marie-Hélène Massicotte et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Stevens-Johnson Syndrome Induced by Vandetanib
- (2012) Jimi Yoon et al. Annals of Dermatology
- A New Spectrum of Skin Toxic Effects Associated With the Multikinase Inhibitor Vandetanib
- (2012) Damien Giacchero et al. ARCHIVES OF DERMATOLOGY
- Incidence and risk of hypertension with vandetanib in cancer patients: a systematic review and meta-analysis of clinical trials
- (2012) Wei-Xiang Qi et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Drug induced QT prolongation: the measurement and assessment of the QT interval in clinical practice
- (2012) Geoffrey K. Isbister et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Vandetanib for the Treatment of Symptomatic or Progressive Medullary Thyroid Cancer in Patients with Unresectable Locally Advanced or Metastatic Disease: U.S. Food and Drug Administration Drug Approval Summary
- (2012) K. Thornton et al. CLINICAL CANCER RESEARCH
- Risk of Rash in Cancer Patients Treated with Vandetanib: Systematic Review and Meta-Analysis
- (2012) Alyx C. Rosen et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Vandetanib in locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 2 trial
- (2012) Sophie Leboulleux et al. LANCET ONCOLOGY
- Incidence and Risk of QTc Interval Prolongation among Cancer Patients Treated with Vandetanib: A Systematic Review and Meta-analysis
- (2012) Jiajie Zang et al. PLoS One
- Semiology of skin toxicity associated with epidermal growth factor receptor (EGFR) inhibitors
- (2012) L. Peuvrel et al. SUPPORTIVE CARE IN CANCER
- Vandetanib for the Treatment of Thyroid Cancer
- (2011) P B Langmuir et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Pharmacokinetics of Vandetanib: Three Phase I Studies in Healthy Subjects
- (2011) Paul Martin et al. CLINICAL THERAPEUTICS
- Endocrine Effects of the Tyrosine Kinase Inhibitor Vandetanib in Patients Treated for Thyroid Cancer
- (2011) Maryse Brassard et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Vandetanib in Patients With Locally Advanced or Metastatic Medullary Thyroid Cancer: A Randomized, Double-Blind Phase III Trial
- (2011) Samuel A. Wells et al. JOURNAL OF CLINICAL ONCOLOGY
- Acute effect of palonosetron on electrocardiographic parameters in cancer patients: a prospective study
- (2011) C. Yavas et al. SUPPORTIVE CARE IN CANCER
- Electrocardiographic findings of palonosetron in cancer patients
- (2011) Guzin Gonullu et al. SUPPORTIVE CARE IN CANCER
- Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities
- (2011) Mario E. Lacouture et al. SUPPORTIVE CARE IN CANCER
- Effects of epidermal growth factor receptor inhibitor-induced dermatologic toxicities on quality of life
- (2010) Smita S. Joshi et al. CANCER
- Vandetanib (100 mg) in Patients with Locally Advanced or Metastatic Hereditary Medullary Thyroid Cancer
- (2010) Bruce G. Robinson et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Vandetanib for the Treatment of Patients With Locally Advanced or Metastatic Hereditary Medullary Thyroid Cancer
- (2010) Samuel A. Wells et al. JOURNAL OF CLINICAL ONCOLOGY
- A proposed EGFR inhibitor dermatologic adverse event-specific grading scale from the MASCC skin toxicity study group
- (2010) Mario E. Lacouture et al. SUPPORTIVE CARE IN CANCER
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreDiscover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversation